Focus On Asia
Kyorin signs in-licensing agreement with UBE to grow its new drug pipeline as it chases mid-term deal target.
More than a dozen semaglutide generics hit the Indian market at sharp discounts post LOE for Novo Nordisk’s GLP-1 RA molecule setting the stage for a high-octane battle in the diabetes and obesity segment. Can Novo hold steady amid the avalanche and what are KOLs looking for?
Dizal's Zegfrovy (sunvozertinib), already approved in the US and China for the second-line treatment of NSCLC with EGFR exon 20 insertion mutations, triumphs in the WU-KONG28 Phase III study in the first-line setting.
Natco has announced a 90% difference in the price of its semaglutide generic in multi-dose vials versus originator Novo Nordisk’s Ozempic pen ahead of launch tomorrow as Novo’s patents on the product expire today. Its pen will be 70% cheaper.
Kintor's topical androgen receptor inhibitor KX-826 posts win in China Phase III trial in male androgenetic alopecia, following a Phase III setback in 2023.
After creating a new biosimilars unit, Sandoz is now divesting its generics portfolio in Sub-Saharan Africa to the Strides Pharma group. Strides will acquire or license these brands for an initial $12m plus royalty, placing it among the top five firms in the region
Kanaph Therapeutics and IMbiologics launched successful offerings in the IPO-scarce Korean market in the first quarter, as investors become more selective in their targets.
Multinationals showed up with open arms for partnering with Chinese developers at the recent BIOCHINA meeting, but there were signs approaches are changing and firms are now looking beyond straight licensing.
Spanish firm's CSO Karl Ziegelbauer shares with Scrip his views on potential alliances with Chinese and other companies and what Almirall can bring to the table.
Zydus’s investment in a differentiated drug-device combination for semaglutide has led to a win-win GLP-1 co-marketing deal with Lupin even as the Indian drug regulator keeps a watch on advertising activities
India issues firm advisory on promos for obesity and metabolic disorders therapies ahead of loss of exclusivity for semaglutide later this week, with 50-plus generic brands seen in the wings for a share of the pie. Will Eli Lilly and Novo Nordisk have to tweak their multimedia campaigns?
The Spanish company has set up shop in Shanghai to be closer to current and future dermatology partners.
In an interview with Scrip, Samsung Bioepis’ VP and Innovation Project Lead talks about the newly launched innovation project as well as the firm's strategies and goals in ADCs and other novel therapeutics.
Clinical Data Readout: Jacobio Pharmaceuticals and AstraZeneca's JAB-23E73, a pan-KRAS inhibitor, stands out among its peers as the first to report preliminary Phase I results after completing the dose escalation phase of a China-based clinical study.
China has granted a world-first approval to a cAMP-biased GLP-1R agonist, Sciwind's ecnoglutide, for weight management, following convincing Phase III results.
Qilu’s bifunctional combo of PD-1 and CTLA-4 antibodies hits its marks in a Phase III cervical cancer trial, while Lynk’s JAK1 inhibitor logs similar win in atopic dermatitis.
South Korea's government is expanding initiatives to attract clinical trials, foreign pharma investment and partnerships as it looks to support domestic firms' R&D and international expansion ambitions.
Parexel’s CEO Peyton Howell and India chief Sanjay Vyas talked to Scrip about trials amid global upheavals, the slowdown in big pharma decision-making and pivot in some cases to the FSP model, an evolving DCT definition and India opportunities.
UCB is paying $1bn-plus for global rights to Antengene's ATG-201, an anti-CD19/CD3 T-cell engager, as it looks to build its strength in immunology.
Kyowa Kirin halts all trials with its OX40-targeting antibody rocatinlimab following Kaposi’s sarcoma cases and Amgen's recent return of the asset.